BioCentury This Week Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Apr 14, 2026
Paul Bananos, biopharma analyst tracking big biotech deals and funds. Simone Fishburne, industry editor covering translational science and regional regulatory trends. Steve Usdin, Washington editor focused on FDA policy and first-in-human rules. They debate FDA’s bold plan to shorten preclinical pathways, compare approaches in Australia, China and the U.K., and unpack recent billion-dollar acquisitions and huge new life‑science funds.
AI Snips
Chapters
Transcript
Episode notes
U.S. Plan Is More Transformative Than Other Regulators
- The U.S. proposal is more transformative than Australia, China, or the UK because it seeks to redefine evidentiary standards rather than just speed reviews.
- Steve Usdin notes Australia/China speed via faster processes while FDA aims to change required evidence itself.
Push To Streamline Preclinical Requirements Now
- Companies should push FDA to reassess and streamline specific preclinical requirements like farm tox and excessive stability testing before phase one.
- Steve Usdin relays industry concern that some data requirements are unnecessary or mistimed for early trials.
PDUFA Shift From Penalty To Small Incentive
- PDUFA negotiations shifted from punishing companies that run first-in-human trials abroad to offering a small domestic incentive.
- Steve Usdin reports FDA moved from a proposed $10M penalty to a ~ $2M fee reduction for U.S.-anchored phase one trials.